Epigenetic regulation of L1CAM in endometrial carcinoma: comparison to cancer–testis (CT-X) antigens

详细信息    查看全文

• 作者：Uwe Schirmer (1)
  Heidi Fiegl (2)
  Marco Pfeifer (1)
  Alain G Zeimet (2)
  Elisabeth Müller-Holzner (2)
  Peter K Bode (3)
  Verena Tischler (3)
  Peter Altevogt (1)
  
• 刊名：BMC Cancer
• 出版年：2013
• 出版时间：December 2013
• 年：2013
• 卷：13
• 期：1
• 全文大小：532KB
• 参考文献：1. Gavert N, Ben-Shmuel A, Raveh S, Ben-Ze’ev A: L1-CAM in cancerous tissues. / Expert Opin Biol Ther 2008,8(11):1749-757. CrossRef
  2. Schafer MK, Altevogt P: L1CAM malfunction in the nervous system and human carcinomas. / Cell Mol Life Sci 2010,67(14):2425-437. CrossRef
  3. Kiefel H, Bondong S, Hazin J, Ridinger J, Schirmer U, Riedle S, Altevogt P: L1CAM: a major driver for tumor cell invasion and motility. / Cell Adh Migr 2012,6(4):374-84. CrossRef
  4. Fogel M, Gutwein P, Mechtersheimer S, Riedle S, Stoeck A, Smirnov A, Edler L, Ben-Arie A, Huszar M, Altevogt P: L1 expression as a predictor of progression and survival in patients with uterine and ovarian carcinomas. / Lancet 2003,362(9387):869-75. CrossRef
  5. Fogel M, Mechtersheimer S, Huszar M, Smirnov A, Abu-Dahi A, Tilgen W, Reichrath J, Georg T, Altevogt P, Gutwein P: L1 adhesion molecule (CD 171) in development and progression of human malignant melanoma. / Cancer Lett 2003,189(2):237-47. CrossRef
  6. Boo YJ, Park JM, Kim J, Chae YS, Min BW, Um JW, Moon HY: L1 expression as a marker for poor prognosis, tumor progression, and short survival in patients with colorectal cancer. / Ann Surg Oncol 2007,14(5):1703-711. CrossRef
  7. Bondong B, Kiefel H, Hielscher T, Zeimet AG, Zeillinger R, Pils D, Schuster E, Castillo-Tong DC, Cadron I, Vergote I: Prognostic significance of L1CAM in ovarian cancer and its role in constitutive NFκB activation. / Ann Oncol 2012,23(7):1795-802. CrossRef
  8. Huszar M, Pfeifer M, Schirmer U, Kiefel H, Konecny GE, Ben-Arie A, Edler L, Munch M, Muller-Holzner E, Jerabek-Klestil S: Up-regulation of L1CAM is linked to loss of hormone receptors and E-cadherin in aggressive subtypes of endometrial carcinomas. / J Pathol 2010,220(5):551-61. CrossRef
  9. Kallunki P, Edelman GM, Jones FS: Tissue-specific expression of the L1 cell adhesion molecule is modulated by the neural restrictive silencer element. / J Cell Biol 1997,138(6):1343-354. CrossRef
  10. Kuwajima A, Iwashita J, Murata J, Abe T: The histone deacetylase inhibitor butyrate inhibits melanoma cell invasion of Matrigel. / Anticancer Res 2007,27(6B):4163-169.
  11. Kato K, Maesawa C, Itabashi T, Fujisawa K, Otsuka K, Kanno S, Tada H, Tatemichi Y, Kotani K, Oikawa H: DNA hypomethylation at the CpG island is involved in aberrant expression of the L1 cell adhesion molecule gene in colorectal cancer. / Int J Oncol 2009,35(3):467-76.
  12. Bert SA, Robinson MD, Strbenac D, Statham AL, Song JZ, Hulf T, Sutherland RL, Coolen MW, Stirzaker C, Clark SJ: Regional activation of the cancer genome by long-range epigenetic remodeling. / Cancer Cell 2013,23(1):9-2. CrossRef
  13. Konecny GE, Venkatesan N, Yang G, Dering J, Ginther C, Finn R, Rahmeh M, Fejzo MS, Toft D, Jiang SW: Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. / Br J Cancer 2008,98(6):1076-084. CrossRef
  14. Pfeifer M, Schirmer U, Geismann C, Schafer H, Sebens S, Altevogt P: L1CAM expression in endometrial carcinomas is regulated by usage of two different promoter regions. / BMC Mol Biol 2010, 11:64. CrossRef
  15. Mechtersheimer S, Gutwein P, Agmon LN, Stoeck A, Oleszewski M, Riedle S, Postina R, Fahrenholz F, Fogel M, Lemmon V: Ectodomain shedding of L1 adhesion molecule promotes cell migration by autocrine binding to integrins. / J Cell Biol 2001,155(4):661-74. CrossRef
  16. Gast D, Riedle S, Issa Y, Pfeifer M, Beckhove P, Sanderson MP, Arlt M, Moldenhauer G, Fogel M, Kruger A: The cytoplasmic part of L1-CAM controls growth and gene expression in human tumors that is reversed by therapeutic antibodies. / Oncogene 2008,27(9):1281-289. CrossRef
  17. Eads CA, Danenberg KD, Kawakami K, Saltz LB, Blake C, Shibata D, Danenberg PV, Laird PW: MethyLight: a high-throughput assay to measure DNA methylation. / Nucleic Acids Res 2000,28(8):E32. CrossRef
  18. Muller HM, Widschwendter A, Fiegl H, Ivarsson L, Goebel G, Perkmann E, Marth C, Widschwendter M: DNA methylation in serum of breast cancer patients: an independent prognostic marker. / Cancer Res 2003,63(22):7641-645.
  19. Takai D, Jones PA: The CpG island searcher: a new WWW resource. / In Silico Biol 2003,3(3):235-40.
  20. Bock C, Reither S, Mikeska T, Paulsen M, Walter J, Lengauer T: BiQ Analyzer: visualization and quality control for DNA methylation data from bisulfite sequencing. / Bioinformatics 2005,21(21):4067-068. CrossRef
  21. Kohl A, Giese KP, Mohajeri MH, Montag D, Moos M, Schachner M: Analysis of promoter activity and 5-genomic structure of the neural cell adhesion molecule L1. / J Neurosci Res 1992,32(2):167-77. CrossRef
  22. Geismann C, Arlt A, Bauer I, Pfeifer M, Schirmer U, Altevogt P, Muerkoster SS, Schafer H: Binding of the transcription factor Slug to the L1CAM promoter is essential for transforming growth factor-beta1 (TGF-beta)-induced L1CAM expression in human pancreatic ductal adenocarcinoma cells. / Int J Oncol 2011,38(1):257-66.
  23. Gavert N, Conacci-Sorrell M, Gast D, Schneider A, Altevogt P, Brabletz T, Ben-Ze’ev A: L1, a novel target of beta-catenin signaling, transforms cells and is expressed at the invasive front of colon cancers. / J Cell Biol 2005,168(4):633-42. CrossRef
  24. Wischnewski F, Pantel K, Schwarzenbach H: Promoter demethylation and histone acetylation mediate gene expression of MAGE-A1, -A2, -A3, and -A12 in human cancer cells. / Mol Cancer Res 2006,4(5):339-49. CrossRef
  25. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ: Cancer/testis antigens, gametogenesis and cancer. / Nat Rev Cancer 2005,5(8):615-25. CrossRef
  26. Sahin U, Tureci O, Chen YT, Seitz G, Villena-Heinsen C, Old LJ, Pfreundschuh M: Expression of multiple cancer/testis (CT) antigens in breast cancer and melanoma: basis for polyvalent CT vaccine strategies. / Int J Cancer 1998,78(3):387-89. CrossRef
  27. Otto SP, Walbot V: DNA methylation in eukaryotes: kinetics of demethylation and de novo methylation during the life cycle. / Genetics 1990,124(2):429-37.
  28. The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1471-2407/13/156/prepub
  
• 作者单位：Uwe Schirmer (1)
  Heidi Fiegl (2)
  Marco Pfeifer (1)
  Alain G Zeimet (2)
  Elisabeth Müller-Holzner (2)
  Peter K Bode (3)
  Verena Tischler (3)
  Peter Altevogt (1)
  
  1. Department of Translational Immunology, German Cancer Research Center, D015, Heidelberg, D, 69120, Germany
  2. Department of Gynecology and Obstetrics, Medical University of Innsbruck, Innsbruck, A, 6020, Austria
  3. Institute of Surgical Pathology, University Hospital Zürich, Zürich, Switzerland
  
• ISSN：1471-2407

文摘

Background L1CAM was originally identified as an adhesion molecule involved in neural development. In many human carcinomas L1CAM is over-expressed and is associated with a bad prognosis. We previously reported that L1CAM was absent in the vast majority of endometrioid endometrial carcinomas (ECs) (type 1) but was strongly expressed in the more aggressive serous and clear-cell ECs (termed type 2). The differential regulation of L1CAM in ECs is not well understood. Recent evidence suggests that it can be regulated by epigenetic mechanisms. Here we investigated the role of DNA-methylation of the L1CAM promoter for expression. We also studied the relationship to cancer testis (CT-X) antigens that co-localize with L1CAM on chromosome Xq28, a region that is often activated in human tumors. Methods We used EC cell lines and primary tumor tissues for our analysis. For expression analysis we employed RT-PCR and Western blotting. DNA-Methylation of the L1CAM promoter was determined after bisulfite conversation and DNA sequencing. Tumor tissues were examined by immunohistochemical (IHC) staining. Results We demonstrate that the treatment of L1CAM low/negative expressing EC cell lines with 5-/sup>-Azacytidine (5-AzaC) or knock-down of DNMT1 (DNA methyltransferase 1) as well as the HDAC (histone deacetylase) inhibitor Trichostatin A (TSA) up-regulated L1CAM at the mRNA and protein level. The L1CAM gene has two promoter regions with two distinct CpG islands. We observed that the expression of L1CAM correlated with hypermethylation in promoter 1 and 5-AzaC treatment affected the DNA-methylation pattern in this region. The CT-X antigens NY-ESO-1, MAGE-A3 and MAGE-A4 were also strongly up-regulated by 5-AzaC or knock-down of DNMT1 but did not respond to treatment with TSA. Primary EC tumor tissues showed a variable methylation pattern of the L1CAM promoter. No striking differences in promoter methylation were observed between tumor areas with L1CAM expression and those without expression. Conclusions L1CAM expression correlated with methylation of the L1CAM promoter in EC cell lines. In negative cell lines L1CAM expression is up-regulated by epigenetic mechanism. Although genes localized on Xq28 are often re-expressed by human tumors, L1CAM and CT-X antigens show distinct regulation in response to HADC inhibitors and 5-AzaC.